Early Onset Pulmonary Events and Management Strategies during the Treatment of 
ALK Positive NSCLC Patients with Brigatinib

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its rearrangements occur in non-small cell lung cancer (NSCLC), resulting in signal dysregulation in kinase domain. As a new generation of potent ALK tyrosine kinase inhibitors (TKIs), Brigatinib was approved in China in March 2022 a...

Full description

Bibliographic Details

Published in:	Chinese Journal of Lung Cancer
Main Authors:	Mingyi YANG, Weichi LUO, Qing ZHOU
Format:	Article
Language:	Chinese
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-04-01
Subjects:	lung neoplasms anaplastic lymphoma kinase early-onset pulmonary events brigatinib
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.12